Mineralys Therapeutics (MLYS) shares were up premarket Monday after the company said lorundrostat met primary endpoints in both the phase 3 Launch-HTN and phase 2 Advance-HTN trials in patients with uncontrolled hypertension or resistant hypertension.

The company said the phase 3 study showed a statistically significant drop in systolic blood pressure compared with placebo by week six until week 12.

In the phase 2 trial, lorundrostat also led to a statistically significant placebo-adjusted drop of 7.9 mmHg in systolic pressure at week 12, Mineralys said.

Mineralys said the treatment was generally well tolerated in both studies, with low rates of serious side effects and elevated potassium levels. The company said it plans to present more data at a medical conference later this month and continue collecting longer-term results in an extension study.